93), ALT (P=0.78), AST (P=1.00), GGT (P=0.48), HOMA-IR (P=0.78), leptin (P=0.53) or adiponectin (P=0.20). There were no significant clinical or laboratory safety issues observed. Conclusion: High-dose oral vitamin D supplementation for 6 months, while safe, appears to have no impact on liver histology, liver biochemistry, insulin resistance nor adipo-cytokine profile in a pilot cohort of patients with NASH. Disclosures: Matthew T. Kitson – Consulting: MSD, Roche; Grant/Research Support: MSD; Speaking and Teaching: Janssen-Cilag Stuart K. Roberts – Board Membership: Jannsen, Roche, Gilead,

BMS The following people have nothing to disclose: Alan Pham, Adam Gordon, Wil-iam W. Kemp, Peter Button Background: Liver stiffness measurement (LSM) by vibration controlled transient elastography using FibroScan® is a promising tool for non-invasive diagnosis liver fibrosis in patients this website Opaganib datasheet with non-alcoholic fatty liver disease (NAFLD). FibroScan® is available for use with M probe (transducer frequency is 3.5 MHz) designed for the general adult population and the more recent XL probe (transducer frequency of 2.5 MHz) for overweight patients. Aim: The aim of the current study is to compare accuracy of M and XL probes for the diagnosis of clinically significant NAFLD. Methods: Patients with biopsy proven

NAFLD (duration between liver biopsy and LSM <1 year) or NASH related cirrhosis were identified from an IRB approved prospective database of patients undergoing Fibroscan. Patients with clinically significant fibrosis were identified based on METAVIR stage >F2 or presence of clinically obvious cirrhosis. Results:

A total of 94 patients (61% female, 94% Caucasian) with mean age of 54 ± 10 years and BMI of 34 ± 7 kg/m2 qualified for the current study. Clinically significant fibrosis was present in 70% (n=66). LSM was estimated using M probe in 56 (60%) and XL probe in 38 (40%) patients. LSM measurement could not be measured in 1 patient with overall failure rate of 1%. The mean LSM was significantly higher Cyclooxygenase (COX) in NAFLD patients with clinically significant fibrosis in patients who underwent the study either by M probe (25.0 ± 17.6 vs. 9.5 ± 4.4 kPa, p-val <0.001) or XL probe (18.8 ± 13.1 vs. 8.1 ± 3.4 kPa, p-val<0.001). The accuracy for the diagnosis of clinically significant fibrosis was very good for both M and XL probes (AUROC of 0.837 and 0.826 for M and XL probes respectively) (Figure 1). With the exception of BMI (30.4 ± 4.6 vs. 39.5 ± 6.1, kg/m2, p-val<0.001), there were no statistically significant differences in liver biochemistries or other parameters (AST, ALT, total bilirubin, platelet count, and albumin) between the patients that underwent LSM measurements with M and XL probes respectively. Conclusion: LSM as measured by M or XL probes has similar accuracy for the diagnosis of clinically significant fibrosis in patients with NAFLD. AUROC in M and XL probe Disclosures: Naga P.